Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2interventionalRules rewrite

Phase 2: Dose de-escalation to contralateral neck. for Head and Neck Cancer

Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have very good outcomes. Patients' treatment responses depend more on their individual cancer characteristics and personal risk factors than on the specific type of treatment they receive.

Official registry: https://clinicaltrials.gov/study/NCT07418034 · University of Maryland, Baltimore · enrollment listed as 132

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, or Dose de-escalation to gross disease. The registry lists allocation as na. Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have very good outcomes.

They plan to enroll about 132 people at 4 sites. Taking part typically means a procedure as part of the study plus check-ins.

Official title (unrewritten)

A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)

Interventions: Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease, Circulating Tumor DNA test (ctDNA test)

Primary outcome (registry wording): Freedom From Regional Failures (FFRF)

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • 1 Step 1 Registration 4.1.1 Step 1 Inclusion
  • (Y) 2. Is the patient ≥ 18 years of age?
  • (Y) 4. Clinical TNM staging criteria by cohort (AJCC 8th edition):
  • TORS candidate patients must be:
  • cT0-4 and N0, N1, N3
  • Non-TORS candidate patients must be either:
  • cT1-3 N2 with \< 10 pack years

Public study contact (from the registry)

Jason K Molitoris

410-328-6080

jmolitoris@umm.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

4 listed

Related recruiting trials in this snapshot

RecruitingPhase 1 / Phase 2Duarte, California
Phase 1 / Phase 2: testing INBRX-106 - Hexavalent OX40 agonist antibody for Solid Tumor

This is a Phase 1/2, open-label, non-randomly assigned, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.

NCT04198766 · Official ClinicalTrials.gov record · Inhibrx Biosciences, Inc

RecruitingPhase 2Phoenix, Arizona
Phase 2: testing Cabozantinib S-malate for Clinical Stage III Cutaneous Melanoma AJCC v8

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT05136196 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBasking Ridge, New Jersey
Not a traditional drug phase: Neurocognitive Tests for Head and Neck Cancer

The researchers are doing this study to collect more information about if, and how, neurocognitive function may be affected in people being treated with radiation therapy for head and neck cancer. Part of this study is to see if patients diagnosed with head and neck cancer who are undergoing radiation therapy are able to complete neurocognitive testing and questionnaires at 3 times over a period of 1 year.

NCT05207098 · Official ClinicalTrials.gov record · Memorial Sloan Kettering Cancer Center

FAQ about this NCT record

Is NCT07418034 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07418034?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07418034?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary